managing-viscosity-in-highconcentration-formulations
High-concentration biologic formulations often struggle with prohibitive viscosity, making manufacturing difficult and patient delivery challenging. Discover practical strategies to effectively manage viscosity, ensuring stable and patient-friendly subcutaneous injections.
Menu
Taming the Syrup: A Practical Guide to Managing Viscosity in High-Concentration Formulations
FAQ
1. Current Situation
2. Typical Market Trends
3. Current Challenges and How They Are Solved
4. How Leukocare Can Support These Challenges[21, 24]
5. Value Provided to Customers
Taming the Syrup: A Practical Guide to Managing Viscosity in High-Concentration Formulations
For anyone in drug product development, the challenge is familiar: get a stable, effective biologic to patients in a way that works for them. Increasingly, that means developing a high-concentration formulation for subcutaneous (SC) injection. But as we pack more protein into a small volume, a physical property becomes a major hurdle: viscosity. Turning a biologic solution into something thick like honey creates problems for manufacturing, stability, and patient delivery. Getting viscosity right is less about finding a single magic bullet and more about smart, strategic formulation design.
1. Current Situation
High-concentration formulations, usually over 100 mg/mL, aren't just for special cases anymore; they're a main goal for many monoclonal antibody (mAb) projects. The main reason is the switch from intravenous (IV) to subcutaneous (SC) delivery.[22, 3] Patients often like SC injections better because they're convenient, letting them inject at home and skip long hospital visits.[4] This change makes things easier for healthcare systems and can also bring down the total cost of treatment.[3, 7, 22]
When protein concentrations go up, protein-protein interactions also increase, which can significantly raise the solution's viscosity. This isn't just a small problem. High viscosity can make a drug impossible to produce with standard equipment or inject with a syringe.[3, 9, 22] It makes sterile filtration and fill-finish steps harder, and can even hurt the drug's stability by causing aggregation.[10]
2. Typical Market Trends
The biologics market keeps getting bigger, and there's a clear move toward solutions that put patients first. The market for subcutaneous drug delivery devices is expected to grow a lot, showing how much people want therapies they can give themselves.[11, 12] A few big reasons are driving this trend:
Patient Convenience and Adherence: Giving injections at home is a big reason for patients who have ongoing health issues.[13, 14] A quick shot is way more convenient than a long IV drip and can really change how good a patient's life is and help them stick to their treatment.[4]
Healthcare Economics: When patients can give themselves SC injections instead of getting IVs from a clinician, it can save healthcare systems a lot of money by cutting down on hospital resources.[7]
Lifecycle Management: For existing biologic drugs, making a subcutaneous version is a common way to make the drug more valuable for longer and give a more competitive choice.[15]
These trends show that we'll always need high-concentration, low-viscosity formulations. It's now a must-have to do well in the market.
3. Current Challenges and How They Are Solved
Dealing with viscosity is a balancing act. You want the viscosity to be low enough to actually use it, typically below 20-25 mPa·s for comfortable injection with standard devices, without messing up the protein's stability.
The Challenges:[16, 27]
Manufacturability: Very thick solutions are hard to work with. They can slow down or even stop ultrafiltration/diafiltration (UF/DF) steps and cause problems when pumping and filling.
Injectability: A formulation that's too thick is hard for a patient to inject. It can need too much force for a standard syringe or auto-injector, which can cause pain and mean they don't get the full dose.[10]
Stability: The same molecular interactions that make it thick can also cause aggregation and particles to form, which is a big deal for quality and safety.[16, 27]
Common Solutions:[1, 20, 8]
Usually, people screen a lot of excipients, the other ingredients in the formulation. This is often a trial-and-error process.[9] Common things that make it less thick include salts, sugars, and certain amino acids like arginine, proline, and histidine. These molecules seem to work by getting in the way of protein interactions that cause high viscosity.[21, 24] But finding the perfect mix isn't easy, because something that makes it less thick might also make the protein unstable.
4. How Leukocare Can Support These Challenges[21, 24]
Just screening a bunch of common excipients can be slow and uses a lot of material. This is extra hard for new companies, where every bit of protein counts. We need a more modern, data-focused way to go from guessing to smart design.
This is where working together, based on predicting outcomes, can really make a difference. Instead of just doing a screening plan, we act as a smart partner. By putting together our deep knowledge of formulations with advanced digital tools, we can handle viscosity problems better. We use an AI platform that helps predict how different excipient mixes will affect a molecule's stability and thickness.
This data-driven method helps us:
Focus our experiments: Instead of testing tons of candidates, our predictive models find a smaller, more hopeful group of formulations. This saves a lot of time and material.
Understand the "Why": We really try to understand why a specific molecule gets so thick. This deeper understanding helps us find stronger, more dependable solutions.[25, 26, 28, 29]
Make development less risky: By seeing problems coming early on, we help put together strong data and a convincing CMC story. This gives development teams (and their investors) trust that the formulation is based on good science.
For a fast-track biotech, this means a quicker, cleaner path to the clinic. For a mid-sized company working on a new or tough molecule, it means getting expert help to solve a tricky problem without messing up what they're already doing.
5. Value Provided to Customers
Working with a formulation partner should do more than just give you a vial of liquid. It should give real value that moves the entire project forward.
Speed and Efficiency: A smart, data-driven plan for formulation gets you to a usable candidate faster. It cuts down on pointless experiments and speeds up how fast you get to important decisions.
Reliable, Commercial-Ready Formulations: The aim is a formulation that's not just stable in the lab, but can also be made in large amounts and is ready for regulators to check. Because we focus on predictive modeling and really understanding the science, we help make sure the final formulation is strong.
A True Partnership: Development teams are under a lot of pressure. They need a partner who thinks ahead and brings solutions, not just data. By working as part of your team, we help you get through the tricky parts of formulation development, giving you clear communication and results you can count on.
Managing viscosity is a really important step in creating a successful biologic drug. By going beyond traditional screening and using a more predictive, science-backed approach, we can solve this problem and provide formulations that work for manufacturers, regulators, and most importantly, patients.
FAQ
1. At what stage should we start thinking about viscosity?
As soon as you can. Early checks can tell if a molecule might have viscosity issues when it's highly concentrated. Dealing with this while choosing candidates can save a lot of time and money later.
2. What is a typical target viscosity for a subcutaneous formulation?
It depends on the delivery device, but usually, we aim for below 20-25 mPa·s. You can sometimes give formulations with viscosity up to about 50 cP, but that might need special devices and could be less comfy for the patient.[16, 27]
3. How does an AI-driven platform accelerate viscosity reduction compared to traditional methods?
Old ways mostly depend on physical screening, which takes a lot of time and uses tons of material. An AI platform uses machine learning to create predictive models from smaller sets of data.[10] This leads to a more focused and smart screening approach, finding the best excipient mixes much faster and with more certainty.[25, 28]
4. Can viscosity issues be solved with excipients alone?
Often, but not always. Excipients are the main tool to cut down on viscosity, but whether it works depends on the specific protein.[26, 29] If protein interactions are super strong, you might need to change the molecule itself through protein engineering to get the right thickness at high concentrations.[22, 3]
